Up to 15 million equity investment from US-based Northpond Ventures will accelerate commercial expansion in North America and global markets. SpeeDx collaborates with key researchers and organizations around the globe with a shared goal of providing clinicians with the information and guidance they need to address the urgent issues related to antibiotic resistance and better management of infectious diseases.
“SpeeDx has developed significant strategic partnerships and their recent successes demonstrate true global potential,” said Michael Rubin M.D., Ph.D., Founder and CEO of Northpond Ventures. “They are positioned to become a world leader with technology that will benefit millions of patients globally.”
Read the full press release.